EU Crunch Time For Diurnal’s Potentially 'Transformational' Rare Disease Drug

The European Medicines Agency is deciding on the EU marketing application for Chronocort, a life-long treatment for congenital adrenal hyperplasia.

UK and EU flags
Marketing applications for Chronocort are under review in the both the EU and the UK • Source: Shutterstock

Diurnal Group could learn this week whether the European Medicines Agency will recommend pan-EU marketing authorization for Chronocort (modified-release hydrocortisone), the UK company’s replacement therapy for the rare condition congenital adrenal hyperplasia (CAH).

Chronocort is not yet approved in any country. It is among the new medicines that are listed on the

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography